Catalyst Wire Dossier Catalyst Wire Dossier

Adalimumab-680LT

adalimumab
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Adalimumab-680LT, covering 2024-03-12 to 2026-01-14. Get the full timeline:

Most recent: Clinical Trial Update: Fluorescence Imaging of Adalimumab-680LT and Risankizumab-800CW in Inflammatory Bowel Disease [Phase 1, Phase 2]

See pricing